Comments
Bharat Biotech’s Covid-19 vaccine candidate, Covaxin, ‘effectively neutralises’ the UK variant of the coronavirus, says a research study.
Covaxin also reduces the possibility of mutant virus escape, the findings of the study said in a preprint article which has not been peer reviewed.
The researchers performed the plaque reduction neutralisation test using sera collected from 26 recipients of Covaxin against Covid-19’s India and UK variants.
“Comparable neutralisation activity of sera of the vaccinated individuals showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralisation escape,” the paper said.
Covaxin is now undergoing Phase III trials in India even as it is being administered to healthcare workers as part of emergency use.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.